Evaluation of a 12-week allopurinol-lowering therapy in combination with the non-steroidal anti-inflammatory drug meloxicam in patients with gout

Cover Page


Aim. To evaluate a 12-week course of combined alloturinol-lowering therapy with a prophylactic anti-inflammatory dose of movalis for the frequency of exacerbations and the quality of life of patients with gout.

Materials and methods. Allopurinol was administered orally, 1 time per day. Every 3 weeks, the dosage of the drug was increased by 50 mg to 300 mg per day under the control of the level of serum uric acid (sUA). The total daily dose of the drug movalis, used in the form of different dosage forms, was 7.5–15 mg. The clinical effectiveness of the treatment was evaluated after 3, 6, 9 and 12 weeks according to physical examination, the dynamics of joint pain at rest, during movement and palpation, according to the visual analogue scale (VAS) in millimeters, Likert scale, EuroQol-5D-5L questionnaire, care for oneself, habitual daily activities, the presence of anxiety and depression, assessment of satisfaction with treatment (on a scale of 1 to 5, where 1 is the complete absence of improvement or worsening, and 5 is a very good result); took into account the period of remission, as well as the time before the onset of relapse of gouty arthritis. An adverse event (AE) was recorded.

Results and discussion. On the background of treatment with movalis 7.5 mg per day more than two-thirds of patients showed no worsening of the articular syndrome with an increase in the dose of allopurinol to 300 mg per day. By the 12th week of observation, a significant difference was found between the severity of gouty arthritis characteristics in the direction of improving mobility, self-care, normal daily activities, reducing soreness, reducing anxiety and depression (p<0.05). In addition, the ESR and sUA levels were significantly different initially and at the final observation point (p<0.05), which indicates a positive effect on the inflammatory process. A 3-month course of combination therapy was not accompanied by significant increases in blood pressure, changes in creatinine clearance in blood serum. There were no adverse events from the gastrointestinal tract. 90.9% of patients rated the treatment result as very good. AE in the form of a skin allergic rash was observed in one patient; it did not require interruption of treatment and completely stopped without consequences after completion of the course.

Conclusion. 12 – a week-long combined therapy of the allopurinol-reducing drug with the anti-inflammatory dose movalis prevents the exacerbation of the articular syndrome and improves the quality of life of patients with gout.

Full Text

Restricted Access

About the authors

Margarita A. Gromova

Pirogov Russian National Research Medical University

Author for correspondence.
Email: margarita-gromov@mail.ru
ORCID iD: 0000-0002-3757-058X

Russian Federation, Moscow

канд. мед. наук, ассистент каф. факультетской терапии лечебного фак-та

Vladimir V. Tsurko

Pirogov Russian National Research Medical University; Sechenov First Moscow State Medical University (Sechenov University)

Email: margarita-gromov@mail.ru
ORCID iD: 0000-0001-8040-3704

Russian Federation, Moscow

д-р мед. наук, проф. каф. общей врачебной практики; проф. каф. факультетской терапии лечебного фак-та

Oksana A. Kislyak

Pirogov Russian National Research Medical University

Email: margarita-gromov@mail.ru
ORCID iD: 0000-0002-2028-8748

Russian Federation, Moscow

д-р мед. наук, проф., зав. каф. факультетской терапии лечебного фак-та

Natalia V. Malysheva

Pirogov Russian National Research Medical University

Email: margarita-gromov@mail.ru
ORCID iD: 0000-0002-3216-9412

Russian Federation, Moscow

канд. мед. наук, доц. каф. факультетской терапии лечебного фак-та


  1. Richette P, Bardin T. Gout. Lancet. 2010;375(9711):318-28. doi: 10.1016/S0140-6736(09)60883-7
  2. Российские клинические рекомендации. Ревматология. Под ред. Е.Л. Насонова. М.: ГЭОТАР-Медиа, 2017; с. 253-65 [Rossiyskiye klinicheskiye rekomendatsii. Revmatologiya. Pod red. E.L. Nasonovа. Moscow: GEOTAR-Media, 2017; p. 253-65 (In Russ.)]. http://www.geotar.ru/lots/NF0005151.html
  3. Martillo MA, Nazzal L, Crittenden DB. The crystallization of monosodium urate. Curr Rheumatol Reports. 2014;16(2):400. doi: 10.1007/s11926-013-0400-9
  4. Richette P, Doherty M, Pascual Е, et al. 2018 updated European League Against Rheumatism evidence-based recommendations for the diagnosis of gout. Ann Rheum Dis. 2019;79(1):31-8. doi: 10.1136/ annrheumdis-2019-215315
  5. Ragab G, Elshahaly M, Bardin T. Gout: An old disease in new perspective – A review. J Advanc Res. 2017;8(5):495-511. doi: 10.1016/j.jare.2017.04.008
  6. Choi HK, Atkinson K, Karlson EW, Curhan G. Purine-rich foods, dairy and protein intake, and the risk of gout in men. New Engl J Med. 2004;350(11):1093-103. doi: 10.1056/nejmoa035700
  7. Zhang Y, Woods R, Chaisson CE, et al. Alcohol consumption as a trigger of recurrent gout attacks. Am J Med. 2006;119(9):800.e11-800.e16. doi: 10.1016/j.amjmed.2006.01.020
  8. Choi HK, Atkinson K, Karlson EW, Curhan G. Obesity, weight change, hypertension, diuretic use, and risk of gout in men: the health professionals follow-up study. Arch Intern Med. 2005;165(7):742-8. doi: 10.1001/archinte.165.7.742
  9. Hootman JM, Helmick CG. Projections of US prevalence of arthritis and associated activity limitations. Arthrit Rheumatol. 2006;54:226-9. doi: 10.1002/art.21562
  10. Newberry SJ, FitzGerald JD, Motala A, et al. Diagnosis of Gout: A Systematic Review in Support of an American College of Physicians Clinical Practice Guideline. Arch Intern Med. 2017;166(1):27-36. doi: 10.7326/M16-0462
  11. Rees F, Jenkins W, Doherty M. Patients with gout adhere to curative treatment if informed appropriately: proof-of-concept observational study. Ann Rheum Dis. 2013;72:826-30. doi: 10.1136/annrheumdis-2012-201676
  12. De Vera MA, Marcotte G, Rai S, et al. Medication adherence in gout: asystematic review. Arth Care Res. 2014;66(10):1551-9. doi: 10.1002/acr.22336
  13. Yin R, Li L, Zhang G, et al. Rate of adherence to urate-loweringtherapy among patients with gout: a systematic review and meta-analysis. BMJ Open. 2018;8(4):e017542. doi: 10.1136/bmjopen-2017-017542
  14. Richette P, Doherty M, Pascual E, et al. Updated EULAR evidence-based recommendations for the management of gout. Ann Rheum Dis. 2016;76(1):29-42. doi: 10.1136/annrheumdis-2016-209707
  15. Цурко В.В., Громова М.А. Рационально-обоснованный подход к лечению подагры с учетом дебюта, течения и сочетанной патологии по материалам рекомендаций Европейской антиревматической лиги (EULAR 2016). Терапевтический архив. 2017;89(12):233-7 [Tsurko VV, Gromova MA. A rationally grounded approach to treating gout with regard to its onset and course and the presence of comorbidity according to the European League against Rheumatism (EULAR 2016) recommendations. Therapeutic Archive. 2017;89(12):233-7 (In Russ.)]. doi: 10.17116/terarkh20178912233-237
  16. Becker MA, MacDonald PA, Hunt BJ, et al. Determinants of the clinical outcomes of gout during the first year of urate-lowering therapy. Nucleosides, Nucleotides Nucleic Acids. 2008;27:585-91. doi: 10.1080/15257770802136032
  17. Wortmann RL, Macdonald PA, Hunt B, Jackson RL. Effect of prophylaxis on gout flares after the initiation of urate-lowering therapy: analysis of data from three phase III trials. Clin Ther. 2010;32:2386-97. doi: 10.1016/j.clinthera.2011.01.008
  18. Kydd AS, Seth R, Buchbinder R, et al. Uricosuric medications for chronic gout. Cochrane Database System Rev. 2014;(11):CD01045. doi: 10.1002/14651858.cd010457.pub2
  19. Hira D, Chisaki Y, Noda S, et al. Population pharmacokinetics and therapeutic efficacy of febuxostat in patients with severe renal impairment. Pharmacology. 2015;96:90-8. doi: 10.1159/000434633
  20. Neogi T. Gout. Ann Intern Med. 2016;165(1):ITC1-ITC16. doi: 10.7326/AITC201607050
  21. Finkelstein Y, Aks SE, Hutson JR, et al. Colchicine poisoning: the dark side of an ancient drug. Clin Toxicol. 2010;48:407-14. doi: 10.3109/15563650.2010.495348
  22. Keenan RT, O’Brien WR, Lee KH, et al. Prevalence of contra indications and prescription of pharmacologic therapies for gout. Am J Med. 2011;124:155-63. doi: 10.1016/j.amjmed.2010.09.012
  23. Asghar W, Jamali F. The effect of COX-2-selective meloxicam on the myocardial, vascular and renal risks: a systematic review. Inflammopharmacol. 2015;23(1):1-16. doi: 10.1007/s10787-014-0225-9
  24. Yang M, Wang HT, Zhao M, et al. Network Meta-Analysis Comparing Relatively Selective COX-2 Inhibitors Versus Coxibs for the Prevention of NSAID-Induced Gastrointestinal Injury. Medicine. 2015;94(40):e1592. doi: 10.1097/md.0000000000001592
  25. Arfè A, Scotti L, Varas-Lorenzo C, et al. Non-steroidal anti-inflammatory drugs and risk of heart failure in four European countries: nested case-control study. BMJ. 2016:i4857. doi: 10.1136/bmj.i4857
  26. Varas-Lorenzo C, Riera-Guardia N, Calingaert B, et al. Myocardial infarction and individual nonsteroidal anti-inflammatory drugs meta-analysisof observational studies. Pharmacoepidemiol Drug Safety. 2013;22(6):559-70. doi: 10.1002/pds.3437
  27. ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J. 2018 Sep 1;39(33):3021-104. doi: 10.1093/eurheartj/ ehy339, published 25.08.2018
  28. ESC Guidelines for the Diagnosis and Management of Chronic Coronary Syndromes: The Task Force for the Diagnosis and Management of Chronic Coronary Syndromes of the European Society of Cardiology (ESC). Eur Heart J. 2020;41(3):407-77. doi: 10.1093/eurheartj/ehz425
  29. Roglic G, Norris SL. Medicines for treatment intensification in type 2 diabetes and type of insulin in type 1 and type 2 diabetes in low-resource settings: Synopsis of the World Health Organization guidelines on second- and third-line medicines and type of insulin for the control of blood glucose levels in nonpregnant adults with diabetes mellitus. Ann Intern Med. 2018;169(6):394. doi: 10.7326/M18-1149
  30. Humphrey LL, Kansagara D, Qaseem A, for the High Value Care Committee of the American College of Physicians. World Health Organization guidelines on medicines for diabetes treatment intensification: Commentary from the American College of Physicians high value care committee. Ann Intern Med. 2018;169(6):398. doi: 10.7326/M18-1148
  31. National Kidney Foundation. K/DOQI Clinical Practice Guidelines for Chronic Kidney Disease: Evaluation, Classification and Stratification. Am J Kidney Dis. 2002;39(Suppl. 1):1-266. https://www.ncbi.nlm.nih.gov/pubmed/11904577
  32. KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. 2013. https://kdigo.org/wp-content/uploads/2017/02/KDIGO_2012_CKD_GL.pdf
  33. Wittens C, Davies AH, Bækgaard N, et al. Editor’s Choice – Management of Chronic Venous Disease: Clinical Practice Guidelines of the European Society for Vascular Surgery (ESVS). Eur J Vasc Endovasc Surg. 2015;49(6):678-737. doi: 10.1016/j.ejvs.2015.02.007
  34. Hawker GA, Mian S, Kendzerska T, French M. Measures of adult pain: Visual Analog Scale for Pain (VAS Pain), Numeric Rating Scale for Pain (NRS Pain), McGill Pain Questionnaire (MPQ), Short-Form McGill Pain Questionnaire (SF-MPQ), Chronic Pain Grade Scale (CPGS), Short Form-36 Bodily Pain Scale (SF-36 BPS), and Measure of Intermittent and Constant Osteoarthritis Pain (ICOAP). Arth Care Res. 2011;63(Suppl. 11):S240-S252. doi: 10.1002/acr.20543
  35. McLeod S. Likert Scale Definition, Examples and Analysis. 2019. https://www.simplypsychology.org/likert-scale.html.
  36. Амирджанова В.Н., Эрдес Ш.Ф. Валидация русской версии общего опросника EuroQol-5D (EQ-5D). Научно-практическая ревматология. 2007;45(3):69-76 [Amirdjanova VN, Erdes SF. Validation of general questionnaire EuroQol-5D (EQ-5D). Nauchno-prakticheskaya revmatologiya. 2007;45(3):69-76 (In Russ.)]. doi: 10.14412/1995-4484-2007-691



Abstract - 45

PDF (Russian) - 8





  • There are currently no refbacks.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

Address of the Editorial Office:

  • Novij Zykovskij proezd, 3, 40, Moscow, 125167

Correspondence address:

  • Novoslobodskaya str 31c4., Moscow, 127005, Russian Federation

Managing Editor:


© 2018 "Consilium Medicum" Publishing house

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies